Breaking News Instant updates and real-time market news.

ACB

Aurora Cannabis

$15.63 /

-1.47 (-8.60%)

10:24
05/22/20
05/22
10:24
05/22/20
10:24

Aurora Cannabis price target raised to C$24 from C$14 at CIBC

CIBC analyst John Zamparo raised the firm's price target on Aurora Cannabis to C$24 from C$14 and keeps a Neutral rating on the shares following the company's acquisition of Reliva.

  • 04

    Jun

ACB Aurora Cannabis
$15.63 /

-1.47 (-8.60%)

05/22/20
Fly Intel: Top five analyst downgrades
05/22/20 Jefferies
Aurora Cannabis downgraded to Underperform from Hold at Jefferies
05/21/20 Stifel
Stifel keeps Sell rating on Aurora, calls Reliva deal a 'small but good step'
05/21/20 Cantor Fitzgerald
Aurora Cannabis price target raised to C$27 from C$22 at Cantor Fitzgerald

TODAY'S FREE FLY STORIES

General news
FX Update: The yen has strengthened » 03:25
05/29/20
05/29
03:25
05/29/20
03:25

FX Update: The yen has…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

General news
Asian Market Update: » 01:50
05/29/20
05/29
01:50
05/29/20
01:50

Asian Market Update: the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Syndicate
Mersana Therapeutics 8M share Secondary priced at $19.00 » 23:36
05/28/20
05/28
23:36
05/28/20
23:36
MRSN

Mersana Therapeutics

$19.70 /

+1.52 (+8.36%)

The deal size was…

The deal size was increased to 8M shares of common stock from 5M shares of common stock. Cowen and SVB Leerink acted as joint book running managers for the offering.

ShowHide Related Items >><<
MRSN Mersana Therapeutics
$19.70 /

+1.52 (+8.36%)

MRSN Mersana Therapeutics
$19.70 /

+1.52 (+8.36%)

05/27/20 H.C. Wainwright
Mersana Therapeutics price target raised to $26 from $13 at H.C. Wainwright
04/29/20 BTIG
Mersana Therapeutics initiated with a Buy at BTIG
01/21/20 H.C. Wainwright
Mersana Therapeutics price target raised to $12 from $7 at H.C. Wainwright
08/20/19 H.C. Wainwright
H.C. Wainwright says trial initiation at higher dosing 'bodes well' for Mersana
MRSN Mersana Therapeutics
$19.70 /

+1.52 (+8.36%)

  • 29
    May
MRSN Mersana Therapeutics
$19.70 /

+1.52 (+8.36%)

MRSN Mersana Therapeutics
$19.70 /

+1.52 (+8.36%)

Syndicate
Arcus Biosciences 11M share Secondary priced at $27.05 » 23:29
05/28/20
05/28
23:29
05/28/20
23:29
RCUS

Arcus Biosciences

$28.11 /

+1 (+3.69%)

Citi, SVB Leerink and…

Citi, SVB Leerink and Evercore ISI acted as joint book running managers for the offering.

ShowHide Related Items >><<
RCUS Arcus Biosciences
$28.11 /

+1 (+3.69%)

RCUS Arcus Biosciences
$28.11 /

+1 (+3.69%)

05/27/20 Raymond James
Raymond James keeps Market Perform on Gilead following Arcus partnership
05/27/20 Wedbush
Arcus Biosciences price target raised to $48 from $40 at Wedbush
05/27/20 Piper Sandler
Piper says partnership more favorable for Gilead than outright Arcus purchase
05/14/20 Mizuho
Arcus Biosciences price target raised to $40 from $22 at Mizuho
RCUS Arcus Biosciences
$28.11 /

+1 (+3.69%)

  • 29
    May
RCUS Arcus Biosciences
$28.11 /

+1 (+3.69%)

RCUS Arcus Biosciences
$28.11 /

+1 (+3.69%)

RCUS Arcus Biosciences
$28.11 /

+1 (+3.69%)

Syndicate
Iovance Biotherapeutics 16.9M share Secondary priced at $31.00 » 23:25
05/28/20
05/28
23:25
05/28/20
23:25
IOVA

Iovance Biotherapeutics

$32.67 /

-5.455 (-14.31%)

The deal size was…

The deal size was increased to $525M in common stock from $500M in common stock. Jefferies and Goldman Sachs acted as joint book running managers for the offering.

ShowHide Related Items >><<
IOVA Iovance Biotherapeutics
$32.67 /

-5.455 (-14.31%)

IOVA Iovance Biotherapeutics
$32.67 /

-5.455 (-14.31%)

05/28/20 Piper Sandler
Iovance melanoma data 'fully supportive of approval,' says Piper Sandler
04/29/20 Oppenheimer
Iovance Biotherapeutics price target raised to $43 from $35 at Oppenheimer
04/29/20 H.C. Wainwright
Iovance Biotherapeutics price target raised to $48 from $36 at H.C. Wainwright
04/27/20 Piper Sandler
AACR abstract for Moffitt study positive for Iovance, says Piper Sandler
IOVA Iovance Biotherapeutics
$32.67 /

-5.455 (-14.31%)

  • 29
    May
IOVA Iovance Biotherapeutics
$32.67 /

-5.455 (-14.31%)

IOVA Iovance Biotherapeutics
$32.67 /

-5.455 (-14.31%)

IOVA Iovance Biotherapeutics
$32.67 /

-5.455 (-14.31%)

Syndicate
Marinus Pharmaceuticals 16M share Spot Secondary priced at $2.50 » 23:22
05/28/20
05/28
23:22
05/28/20
23:22
MRNS

Marinus Pharmaceuticals

$2.80 /

-0.27 (-8.79%)

The deal range was…

The deal range was $2.50-$2.75. Cowen and Cantor Fitzgerald acted as joint book running managers for the offering.

ShowHide Related Items >><<
MRNS Marinus Pharmaceuticals
$2.80 /

-0.27 (-8.79%)

MRNS Marinus Pharmaceuticals
$2.80 /

-0.27 (-8.79%)

04/09/20 Craig-Hallum
Marinus Pharmaceuticals initiated with a Buy at Craig-Hallum
01/10/20 H.C. Wainwright
Marinus Pharmaceuticals price target raised to $6 from $5 at H.C. Wainwright
12/20/19
Fly Intel: Top five analyst initiations
12/19/19 Oppenheimer
Marinus Pharmaceuticals initiated with an Outperform at Oppenheimer
MRNS Marinus Pharmaceuticals
$2.80 /

-0.27 (-8.79%)

  • 29
    May
MRNS Marinus Pharmaceuticals
$2.80 /

-0.27 (-8.79%)

Syndicate
Boston Omaha 3.2M share Secondary priced at $16.00 » 23:20
05/28/20
05/28
23:20
05/28/20
23:20
BOMN

Boston Omaha

$16.48 /

-2.93 (-15.10%)

Wells Fargo and Cowen…

Wells Fargo and Cowen acted as joint book running managers for the offering.

ShowHide Related Items >><<
BOMN Boston Omaha
$16.48 /

-2.93 (-15.10%)

  • 29
    May
Upgrade
Ares Management upgraded to Outperform from Market Perform at BMO Capital » 21:51
05/28/20
05/28
21:51
05/28/20
21:51
ARES

Ares Management

$36.42 /

-0.72 (-1.94%)

BMO Capital analyst James…

BMO Capital analyst James Fotheringham upgraded Ares Management to Outperform from Market Perform with a price target of $47, up from $40. The company, relative to peers, has seen little disruption to its "significant" near-term fundraising pipeline and its credit-focused platform is well positioned for accelerated capital deployment, Fotheringham tells investors in a research note. He believes Ares shares should benefit from "peer-leading" fee-related earnings growth and organic net flows.

ShowHide Related Items >><<
ARES Ares Management
$36.42 /

-0.72 (-1.94%)

ARES Ares Management
$36.42 /

-0.72 (-1.94%)

04/15/20 Wells Fargo
Ares Management price target lowered to $41 from $50 at Wells Fargo
02/18/20 RBC Capital
Ares Management price target raised to $45 from $38 at RBC Capital
02/18/20 BMO Capital
Ares Management price target raised to $41 from $34 at BMO Capital
12/19/19 Wells Fargo
Wells stays bullish on alternative asset managers into 2020, Ares top pick
ARES Ares Management
$36.42 /

-0.72 (-1.94%)

ARES Ares Management
$36.42 /

-0.72 (-1.94%)

Syndicate
National Fuel 3.8M share Spot Secondary priced at $39.50 » 20:55
05/28/20
05/28
20:55
05/28/20
20:55
NFG

National Fuel

$43.12 /

+0.37 (+0.87%)

The deal size was…

The deal size was increased to 3.8M shares from 3.25M and priced within the $39.00-$41.00 range. JPMorgan, BofA and Goldman Sachs are acting as joint book running managers for the offering.

ShowHide Related Items >><<
NFG National Fuel
$43.12 /

+0.37 (+0.87%)

NFG National Fuel
$43.12 /

+0.37 (+0.87%)

05/07/20 Scotiabank
National Fuel upgraded to Outperform from Sector Perform at Scotiabank
05/07/20 Raymond James
National Fuel upgraded to Outperform from Market Perform at Raymond James
05/07/20 Raymond James
National Fuel upgraded to Outperform from Market Perform at Raymond James
05/06/20 Scotiabank
National Fuel upgraded to Outperform from Sector Perform at Scotiabank
NFG National Fuel
$43.12 /

+0.37 (+0.87%)

  • 29
    May
NFG National Fuel
$43.12 /

+0.37 (+0.87%)

Syndicate
Fiverr 2M share Secondary priced at $60.00 » 20:53
05/28/20
05/28
20:53
05/28/20
20:53
FVRR

Fiverr

$60.54 /

+2.505 (+4.32%)

The deal priced below the…

The deal priced below the last closing price of $60.74. JPMorgan, BofA, Citi and UBS are acting as joint book running managers for the offering.

ShowHide Related Items >><<
FVRR Fiverr
$60.54 /

+2.505 (+4.32%)

FVRR Fiverr
$60.54 /

+2.505 (+4.32%)

05/08/20 JPMorgan
Fiverr price target raised to $54 from $37 at JPMorgan
02/21/20
Fiverr management to meet with Oppenheimer
02/20/20
Fly Intel: Top five analyst upgrades
02/20/20 JPMorgan
Fiverr upgraded to Overweight with $37 price target at JPMorgan
FVRR Fiverr
$60.54 /

+2.505 (+4.32%)

  • 29
    May
FVRR Fiverr
$60.54 /

+2.505 (+4.32%)

FVRR Fiverr
$60.54 /

+2.505 (+4.32%)

Hot Stocks
e.l.f. Beauty confirms receipt of Marathon Partners' notice of board nominees » 20:45
05/28/20
05/28
20:45
05/28/20
20:45
ELF

e.l.f. Beauty

$16.59 /

-0.7 (-4.05%)

e.l.f. Beauty confirmed…

e.l.f. Beauty confirmed that Marathon Partners Equity Management has submitted to the company a notice of nomination of three candidates to stand for election to the company's Board of Directors at the Company's 2020 Annual Meeting of Stockholders. The company issued the following statement: "e.l.f. Beauty welcomes open communications with stockholders and appreciates input that advances our goal of enhancing value. We engage regularly with our stockholders and, to that end, note that members of our Board and senior management team have held numerous discussions and exchanged correspondences with Marathon Partners over the past two years. Our Board is focused on enhancing stockholder value and regularly reviews our business and strategy to ensure that we are best positioned to achieve this goal. We have been aggressively executing our five strategic imperatives to drive demand in the brand, step up our digital efforts, deliver first to mass innovation, enhance retailer productivity and generate cost savings to fuel brand investments. Through the successful execution of these imperatives, we have delivered five consecutive quarters of year on year net sales growth and recharged the e.l.f. brand... Stockholders are not required to take any action at this time. The company's Board of Directors will present its recommendation with respect to the election of directors in the company's definitive proxy statement, which will be filed with the Securities and Exchange Commission and made available to all stockholders eligible to vote at the company's 2020 Annual Meeting of Stockholders, which is scheduled for August 27, 2020. "

ShowHide Related Items >><<
ELF e.l.f. Beauty
$16.59 /

-0.7 (-4.05%)

ELF e.l.f. Beauty
$16.59 /

-0.7 (-4.05%)

05/22/20 SunTrust
e.l.f. Beauty price target raised to $20 from $15 at SunTrust
04/08/20 Piper Sandler
Piper lays out winners and losers in survey of 5,200 teens
03/18/20 DA Davidson
e.l.f. Beauty price target lowered to $12 from $24.50 at DA Davidson
02/06/20 Piper Sandler
e.l.f. Beauty price target raised to $23 from $19 at Piper Sandler
ELF e.l.f. Beauty
$16.59 /

-0.7 (-4.05%)

ELF e.l.f. Beauty
$16.59 /

-0.7 (-4.05%)

ELF e.l.f. Beauty
$16.59 /

-0.7 (-4.05%)

Hot Stocks
Diodes CEO sells 25K shares of common stock » 20:29
05/28/20
05/28
20:29
05/28/20
20:29
DIOD

Diodes

$48.23 /

-2.72 (-5.34%)

In a regulatory filing,…

In a regulatory filing, Diodes discloses that its CEO Lu sold 25K shares of common stock on May 27th-28th in a total transaction size of $1.28M.

ShowHide Related Items >><<
DIOD Diodes
$48.23 /

-2.72 (-5.34%)

DIOD Diodes
$48.23 /

-2.72 (-5.34%)

05/26/20
Fly Intel: Top five analyst initiations
05/26/20 Loop Capital
Diodes initiated with a Buy at Loop Capital
05/26/20 Loop Capital
Diodes initiated with a Buy at Loop Capital
05/21/20 Cowen
Diodes initiated with an Outperform at Cowen
DIOD Diodes
$48.23 /

-2.72 (-5.34%)

DIOD Diodes
$48.23 /

-2.72 (-5.34%)

Upgrade
Culp upgraded to Buy from Hold at Stifel » 20:20
05/28/20
05/28
20:20
05/28/20
20:20
CULP

Culp, Inc.

$6.72 /

-0.1 (-1.47%)

Stifel analyst John Baugh…

Stifel analyst John Baugh upgraded Culp, Inc to Buy from Hold with a price target of $13, up from $8. The stock has fallen to about two-thirds of its tangible book value and now trades close to parity with its net working capital, the analyst tells investors in a research note. Baugh believes however that Culp has sufficient liquidity to survive the downturn, and its key bedding and furniture customers are already seeing a "material rebound" in business.

ShowHide Related Items >><<
CULP Culp, Inc.
$6.72 /

-0.1 (-1.47%)

CULP Culp, Inc.
$6.72 /

-0.1 (-1.47%)

02/19/20
Fly Intel: Top five analyst downgrades
02/19/20 Stifel
Culp, Inc. downgraded to Hold from Buy at Stifel
09/09/19 Raymond James
Culp, Inc. price target lowered to $18 from $22 at Raymond James
CULP Culp, Inc.
$6.72 /

-0.1 (-1.47%)

Hot Stocks
Dine Brands announces CEO search » 20:11
05/28/20
05/28
20:11
05/28/20
20:11
DIN

Dine Brands

$49.12 /

-3.49 (-6.63%)

The board of Dine Brands…

The board of Dine Brands Global announced that it has retained the executive search firm, Spencer Stuart, to assist the company in identifying an individual to succeed its CEO, Steve Joyce. Mr. Joyce's employment agreement expires February 1, 2021.

ShowHide Related Items >><<
DIN Dine Brands
$49.12 /

-3.49 (-6.63%)

DIN Dine Brands
$49.12 /

-3.49 (-6.63%)

04/30/20 MKM Partners
Dine Brands price target raised to $50 from $40 at MKM Partners
04/30/20 Wedbush
Dine Brands price target raised to $60 from $50 at Wedbush
04/20/20 Wedbush
Dine Brands price target lowered to $50 from $110 at Wedbush
02/25/20 MKM Partners
Dine Brands downgraded to Neutral from Buy at MKM Partners
DIN Dine Brands
$49.12 /

-3.49 (-6.63%)

DIN Dine Brands
$49.12 /

-3.49 (-6.63%)

DIN Dine Brands
$49.12 /

-3.49 (-6.63%)

Earnings
Afya reports Q1 net profit R$124.0M, up 131.7% from last year » 19:51
05/28/20
05/28
19:51
05/28/20
19:51
AFYA

Afya

$18.84 /

+0.85 (+4.72%)

Reports Q1 revenue…

Reports Q1 revenue R$272.3M, up 27.2% from last year. Q1 adj. EBITDA increased 36.0% from last year to R$140.6M. CEO Virgilo Gibbon says: "First quarter results grew significantly on the back of the positive dynamics and a very strong intake process concluded by the end of this quarter. Afya had already completed the enrollment process with a 100% occupancy that maintained, as expected, our highly predictable topline growth even during these challenging times. Our business is tracking in line with our first half 2020 expectations as we are successfully executing our long-term strategy and showing the resilience of our business model during this unprecedented crisis. It is worth mentioning that our collection process by end of April is performing even better results when compared to the same period last year, signaling that Afya's strong cash flow generation will continue even during the crisis. Considering the next intake cycle and the additional medical students added after UniSL acquisition, we are expecting to grow 22% our medical student base in 2H20 when compared to 1Q20 reported figures, reaching 9,718 students, attesting the resilience of our business and ability to keep 100% of occupancy rate even during this crisis."

ShowHide Related Items >><<
AFYA Afya
$18.84 /

+0.85 (+4.72%)

AFYA Afya
$18.84 /

+0.85 (+4.72%)

05/20/20 UBS
Afya downgraded to Neutral from Buy at UBS
03/20/20 Itau BBA
Afya upgraded to Outperform from Market Perform at Itau BBA
01/23/20 BofA
Afya reinstated with a Buy at BofA
09/19/19 UBS
Afya initiated with a Buy at UBS
Hot Stocks
Eli Lilly gets FDA approval of Tauvid in patients evaluated for Alzheimer's » 19:23
05/28/20
05/28
19:23
05/28/20
19:23
LLY

Eli Lilly

$150.63 /

+5.02 (+3.45%)

TAUVID, a radioactive…

TAUVID, a radioactive diagnostic agent, has been approved by the FDA for positron emission tomography imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease, or AD. A neuropathological diagnosis of AD requires the demonstration of the presence of both beta-amyloid neuritic plaques and tau NFTs in the brain. TAUVID is the first and only approved diagnostic agent to image tau NFTs in the brain. Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, developed TAUVID and AMYVID to provide physicians with meaningful information on the presence of both pathologies to aid the evaluation of patients suspected of having AD. Availability of TAUVID will initially be limited and will expand in response to commercial demand and payor reimbursement.

ShowHide Related Items >><<
LLY Eli Lilly
$150.63 /

+5.02 (+3.45%)

LLY Eli Lilly
$150.63 /

+5.02 (+3.45%)

04/24/20 Cantor Fitzgerald
Eli Lilly price target raised to $185 from $156 at Cantor Fitzgerald
04/24/20 Mizuho
Eli Lilly price target raised to $155 from $148 at Mizuho
04/21/20
Fly Intel: Top five analyst downgrades
04/21/20 UBS
Eli Lilly downgraded to Neutral from Buy at UBS
LLY Eli Lilly
$150.63 /

+5.02 (+3.45%)

LLY Eli Lilly
$150.63 /

+5.02 (+3.45%)

LLY Eli Lilly
$150.63 /

+5.02 (+3.45%)

Upgrade
AO World upgraded to Buy from Hold at Jefferies » 19:16
05/28/20
05/28
19:16
05/28/20
19:16
AOWDF

AO World

$0.00 /

+ (+0.00%)

Jefferies analyst Andrew…

Jefferies analyst Andrew Wade upgraded AO World to Buy from Hold with a 165 GBp price target. The company has emerged as an online winner of the pandemic lockdown, and while some store demand will return, AO World will gain market share faster than before, the analyst tells investors in a research note. While the stock price has more than doubled in a month, Wade sees as much as 30% additional upside to his new price target.

ShowHide Related Items >><<
AOWDF AO World
$0.00 /

+ (+0.00%)

05/13/20 JPMorgan
AO World price target raised to 101 GBp from 93 GBp at JPMorgan
Recommendations
Sarepta to likely report positive SRP-9003 data next month, says Piper Sandler » 19:07
05/28/20
05/28
19:07
05/28/20
19:07
SRPT

Sarepta

$153.00 /

-4.17 (-2.65%)

Piper Sandler analyst…

Piper Sandler analyst Tyler Van Buren reiterated an Overweight rating and $206 price target on Sarepta, saying he believes the company will likely report positive SRP-9003 data next month and have three approved PMO therapies by the end of the year. The analyst added that the safety and expression data from the LGMD-2E gene therapy high-dose cohort is a "key catalyst," as it should translate to a greater likelihood of success for other five LGMD programs, which current receive "little value."

ShowHide Related Items >><<
SRPT Sarepta
$153.00 /

-4.17 (-2.65%)

SRPT Sarepta
$153.00 /

-4.17 (-2.65%)

05/15/20 Goldman Sachs
After Pfizer data, Goldman says Sarepta remains 'leader' in DMD gene therapy
05/15/20 William Blair
Sarepta remains the leader after Pfizer DMD data, says William Blair
05/15/20 William Blair
Sarepta remains the leader after Pfizer DMD data, says William Blair
05/15/20 JPMorgan
JPMorgan still sees Sarepta in pole position in DMD space
SRPT Sarepta
$153.00 /

-4.17 (-2.65%)

SRPT Sarepta
$153.00 /

-4.17 (-2.65%)

SRPT Sarepta
$153.00 /

-4.17 (-2.65%)

SRPT Sarepta
$153.00 /

-4.17 (-2.65%)

On The Fly
Fly Intel: After-Hours Movers » 19:04
05/28/20
05/28
19:04
05/28/20
19:04
ZS

Zscaler

$75.88 /

+1.34 (+1.80%)

, WSM

Williams-Sonoma

$73.18 /

-0.215 (-0.29%)

, VMW

VMware

$142.79 /

+3.18 (+2.28%)

, DELL

Dell Technologies

$45.55 /

+0.065 (+0.14%)

, MRVL

Marvell

$29.97 /

-0.72 (-2.35%)

, PSTG

Pure Storage

$16.79 /

-0.58 (-3.34%)

, OLLI

Ollie's Bargain Outlet

$88.04 /

-1.93 (-2.15%)

, SNOA

Sonoma Pharmaceuticals

$5.50 /

-0.065 (-1.17%)

, GLUU

Glu Mobile

$8.68 /

-0.185 (-2.09%)

, KPTI

Karyopharm

$18.80 /

-0.02 (-0.11%)

, CRM

Salesforce

$181.35 /

+4.78 (+2.71%)

, VEEV

Veeva

$204.33 /

+12.365 (+6.44%)

, OKTA

Okta

$183.99 /

+4.48 (+2.50%)

, COST

Costco

$310.10 /

+4.16 (+1.36%)

, DXC

DXC Technology

$16.56 /

-1.11 (-6.28%)

, NFG

National Fuel

$43.12 /

+0.37 (+0.87%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
ZS Zscaler
$75.88 /

+1.34 (+1.80%)

WSM Williams-Sonoma
$73.18 /

-0.215 (-0.29%)

VMW VMware
$142.79 /

+3.18 (+2.28%)

VEEV Veeva
$204.33 /

+12.365 (+6.44%)

SNOA Sonoma Pharmaceuticals
$5.50 /

-0.065 (-1.17%)

PSTG Pure Storage
$16.79 /

-0.58 (-3.34%)

OLLI Ollie's Bargain Outlet
$88.04 /

-1.93 (-2.15%)

OKTA Okta
$183.99 /

+4.48 (+2.50%)

NFG National Fuel
$43.12 /

+0.37 (+0.87%)

MRVL Marvell
$29.97 /

-0.72 (-2.35%)

KPTI Karyopharm
$18.80 /

-0.02 (-0.11%)

GLUU Glu Mobile
$8.68 /

-0.185 (-2.09%)

DXC DXC Technology
$16.56 /

-1.11 (-6.28%)

DELL Dell Technologies
$45.55 /

+0.065 (+0.14%)

CRM Salesforce
$181.35 /

+4.78 (+2.71%)

COST Costco
$310.10 /

+4.16 (+1.36%)

ZS Zscaler
$75.88 /

+1.34 (+1.80%)

05/26/20 Cowen
Zscaler price target raised to $80 from $70 at Cowen
05/26/20 Barclays
Zscaler price target raised to $75 from $64 at Barclays
04/24/20
Zscaler cut to Hold at SunTrust on valuation
04/24/20 SunTrust
Zscaler downgraded to Hold from Buy at SunTrust
WSM Williams-Sonoma
$73.18 /

-0.215 (-0.29%)

05/26/20 Telsey Advisory
Williams-Sonoma upgraded to Outperform from Market Perform at Telsey Advisory
05/18/20 Wedbush
Williams-Sonoma upgraded to Outperform at Wedbush
05/18/20 Wedbush
Williams-Sonoma upgraded to Outperform from Neutral at Wedbush
05/14/20 Barclays
Williams-Sonoma price target raised to $72 from $43 at Barclays
VMW VMware
$142.79 /

+3.18 (+2.28%)

05/27/20 BMO Capital
VMware price target lowered to $152 from $163 at BMO Capital
05/26/20 Morgan Stanley
Morgan Stanley sees risk to both Q1 and FY21 for VMware
05/14/20 Jefferies
VMware downgraded to Hold from Buy at Jefferies
03/24/20 Oppenheimer
VMware price target lowered to $165 from $200 at Oppenheimer
DELL Dell Technologies
$45.55 /

+0.065 (+0.14%)

05/26/20 Deutsche Bank
Dell Technologies price target lowered to $52 from $56 at Deutsche Bank
05/19/20 Barclays
Barclays lowers estimates in IT hardware after April survey
04/13/20 Bernstein
Dell Technologies price target lowered to $50 from $60 at Bernstein
MRVL Marvell
$29.97 /

-0.72 (-2.35%)

05/26/20 Susquehanna
Marvell price target raised to $35 from $30 at Susquehanna
05/22/20 B. Riley FBR
Marvell price target raised to $34 from $31 at B. Riley FBR
05/21/20 Cowen
Marvell datapoints indicate softness where they participate, says Cowen
05/21/20 Citi
Marvell price target raised to $35 from $31 at Citi
PSTG Pure Storage
$16.79 /

-0.58 (-3.34%)

03/26/20 Northland
Pure Storage initiated with an Outperform at Northland
03/23/20 Cowen
Pure Storage, Silicon Motion better for bottom fishers, says Cowen
01/17/20 Morgan Stanley
Morgan Stanley downgrades IBM to Equal Weight as IT hardware budgets pressured
OLLI Ollie's Bargain Outlet
$88.04 /

-1.93 (-2.15%)

05/26/20 Craig-Hallum
Ollie's Bargain Outlet upgraded to Buy at Craig-Hallum
05/26/20 Craig-Hallum
Ollie's Bargain Outlet upgraded to Buy from Hold at Craig-Hallum
05/26/20 Credit Suisse
Ollie's Bargain Outlet downgraded to Neutral from Outperform at Credit Suisse
05/18/20
Fly Intel: Top five analyst initiations
SNOA Sonoma Pharmaceuticals
$5.50 /

-0.065 (-1.17%)

GLUU Glu Mobile
$8.68 /

-0.185 (-2.09%)

05/11/20
Fly Intel: Top five analyst downgrades
05/11/20 Morgan Stanley
Morgan Stanley downgrades Glu Mobile after stock nearly doubled
05/10/20 Morgan Stanley
Glu Mobile downgraded to Equal Weight from Overweight at Morgan Stanley
05/08/20 Piper Sandler
Glu Mobile price target raised to $10.50 from $8 at Piper Sandler
KPTI Karyopharm
$18.80 /

-0.02 (-0.11%)

05/06/20 H.C. Wainwright
Karyopharm price target lowered to $40 from $43 at H.C. Wainwright
04/07/20 Wedbush
Wedbush sees signs of 'potential utility' for Karyopharm's selinexor for COVID
04/07/20 H.C. Wainwright
XPO1 inhibitors have shown promise as COVID-19 treatment, says H.C. Wainwright
03/04/20 Barclays
Karyopharm initiated with an Overweight at Barclays
CRM Salesforce
$181.35 /

+4.78 (+2.71%)

05/28/20 Needham
Workday price target raised to $200 from $175 at Needham
05/18/20 Jefferies
Salesforce price target raised to $205 from $180 at Jefferies
05/18/20 RBC Capital
Salesforce price target lowered to $210 from $230 at RBC Capital
05/18/20 Cowen
Salesforce price target lowered to $200 from $220 at Cowen
VEEV Veeva
$204.33 /

+12.365 (+6.44%)

05/27/20 Barclays
Veeva price target raised to $200 from $176 at Barclays
04/13/20 SVB Leerink
Veeva initiated with a Market Perform at SVB Leerink
03/04/20 Piper Sandler
Veeva risk/reward favorable after 'strong' Q4, says Piper Sandler
02/20/20 Morgan Stanley
Veeva set up for 'clean' beat and raise Q4 report, says Morgan Stanley
OKTA Okta
$183.99 /

+4.48 (+2.50%)

05/26/20 Cowen
Okta price target raised to $195 from $150 at Cowen
05/21/20 Baird
Okta price target raised to $185 from $135 at Baird
05/13/20 Cleveland Research
Okta jumps after Cleveland finds strong uptick in license sales
05/04/20 Needham
SailPoint downgraded to Hold from Buy at Needham
COST Costco
$310.10 /

+4.16 (+1.36%)

05/06/20 Baird
Costco SSS decline due to pressure from temporal factors, says Baird
04/15/20 Citi
Costco assumed with a Neutral at Citi
04/14/20 BofA
Amazon.com cost impact of new hires may be offset by higher volumes, says BofA
04/09/20 Loop Capital
Costco price target raised to $355 from $350 at Loop Capital
DXC DXC Technology
$16.56 /

-1.11 (-6.28%)

03/12/20 MoffettNathanson
DXC Technology upgraded to Buy from Neutral at MoffettNathanson
03/11/20 Wells Fargo
DXC Technology price target lowered to $18 from $36 at Wells Fargo
03/11/20 Citi
DXC Technology divestiture proceeds higher than expected, says Citi
02/26/20 Morgan Stanley
DXC Technology resumed with an Overweight at Morgan Stanley
NFG National Fuel
$43.12 /

+0.37 (+0.87%)

05/07/20 Scotiabank
National Fuel upgraded to Outperform from Sector Perform at Scotiabank
05/07/20 Raymond James
National Fuel upgraded to Outperform from Market Perform at Raymond James
05/07/20 Raymond James
National Fuel upgraded to Outperform from Market Perform at Raymond James
05/06/20 Scotiabank
National Fuel upgraded to Outperform from Sector Perform at Scotiabank
ZS Zscaler
$75.88 /

+1.34 (+1.80%)

WSM Williams-Sonoma
$73.18 /

-0.215 (-0.29%)

VMW VMware
$142.79 /

+3.18 (+2.28%)

VEEV Veeva
$204.33 /

+12.365 (+6.44%)

SNOA Sonoma Pharmaceuticals
$5.50 /

-0.065 (-1.17%)

PSTG Pure Storage
$16.79 /

-0.58 (-3.34%)

OLLI Ollie's Bargain Outlet
$88.04 /

-1.93 (-2.15%)

OKTA Okta
$183.99 /

+4.48 (+2.50%)

NFG National Fuel
$43.12 /

+0.37 (+0.87%)

MRVL Marvell
$29.97 /

-0.72 (-2.35%)

KPTI Karyopharm
$18.80 /

-0.02 (-0.11%)

GLUU Glu Mobile
$8.68 /

-0.185 (-2.09%)

DXC DXC Technology
$16.56 /

-1.11 (-6.28%)

DELL Dell Technologies
$45.55 /

+0.065 (+0.14%)

CRM Salesforce
$181.35 /

+4.78 (+2.71%)

COST Costco
$310.10 /

+4.16 (+1.36%)

  • 29
    May
ZS Zscaler
$75.88 /

+1.34 (+1.80%)

VMW VMware
$142.79 /

+3.18 (+2.28%)

MRVL Marvell
$29.97 /

-0.72 (-2.35%)

DXC DXC Technology
$16.56 /

-1.11 (-6.28%)

DELL Dell Technologies
$45.55 /

+0.065 (+0.14%)

CRM Salesforce
$181.35 /

+4.78 (+2.71%)

COST Costco
$310.10 /

+4.16 (+1.36%)

ZS Zscaler
$75.88 /

+1.34 (+1.80%)

WSM Williams-Sonoma
$73.18 /

-0.215 (-0.29%)

VMW VMware
$142.79 /

+3.18 (+2.28%)

VEEV Veeva
$204.33 /

+12.365 (+6.44%)

PSTG Pure Storage
$16.79 /

-0.58 (-3.34%)

OLLI Ollie's Bargain Outlet
$88.04 /

-1.93 (-2.15%)

MRVL Marvell
$29.97 /

-0.72 (-2.35%)

KPTI Karyopharm
$18.80 /

-0.02 (-0.11%)

GLUU Glu Mobile
$8.68 /

-0.185 (-2.09%)

DXC DXC Technology
$16.56 /

-1.11 (-6.28%)

DELL Dell Technologies
$45.55 /

+0.065 (+0.14%)

CRM Salesforce
$181.35 /

+4.78 (+2.71%)

COST Costco
$310.10 /

+4.16 (+1.36%)

ZS Zscaler
$75.88 /

+1.34 (+1.80%)

WSM Williams-Sonoma
$73.18 /

-0.215 (-0.29%)

VMW VMware
$142.79 /

+3.18 (+2.28%)

VEEV Veeva
$204.33 /

+12.365 (+6.44%)

PSTG Pure Storage
$16.79 /

-0.58 (-3.34%)

OLLI Ollie's Bargain Outlet
$88.04 /

-1.93 (-2.15%)

OKTA Okta
$183.99 /

+4.48 (+2.50%)

MRVL Marvell
$29.97 /

-0.72 (-2.35%)

GLUU Glu Mobile
$8.68 /

-0.185 (-2.09%)

DXC DXC Technology
$16.56 /

-1.11 (-6.28%)

DELL Dell Technologies
$45.55 /

+0.065 (+0.14%)

CRM Salesforce
$181.35 /

+4.78 (+2.71%)

COST Costco
$310.10 /

+4.16 (+1.36%)

Hot Stocks
EC releases Takeda from commitment to divest Shire's SHP647 » 19:01
05/28/20
05/28
19:01
05/28/20
19:01
TAK

Takeda Pharmaceutical

$19.22 /

-0.045 (-0.23%)

, SHPG

Acquired by TAK

$179.45 /

+ (+0.00%)

Takeda Pharmaceutical…

Takeda Pharmaceutical (TAK) announced that on May 28, the European Commission has released Takeda from the obligation to divest the pipeline compound SHP647 and certain associated rights, a commitment that was provided by Takeda to secure regulatory clearance of its acquisition of Shire plc (SHPG). Takeda will discontinue the current SHP647 clinical trial program, and it will be providing all eligible trial participants with the opportunity to have continued access to SHP647 in a post-trial access study. In addition, subject to obtaining trial participant consents and the satisfaction of regulatory and ethical considerations, Takeda will make SHP647 clinical trial data and biosamples available to the scientific community through the Crohn's & Colitis Foundation.

ShowHide Related Items >><<
TAK Takeda Pharmaceutical
$19.22 /

-0.045 (-0.23%)

TAK Takeda Pharmaceutical
$19.22 /

-0.045 (-0.23%)

04/20/20 SVB Leerink
Ascendis Pharma price target raised to $170 from $152 at SVB Leerink
03/25/20 Piper Sandler
Piper Sandler backs Overweight on 'well capitalized' Exelixis
03/25/20 Stifel
Molecular Templates initiated with a Buy at Stifel
02/25/20 Stifel
Iovance among 'more interesting' cell therapy takeout candidates, says Stifel
SHPG Acquired by TAK
$179.45 /

+ (+0.00%)

TAK Takeda Pharmaceutical
$19.22 /

-0.045 (-0.23%)

TAK Takeda Pharmaceutical
$19.22 /

-0.045 (-0.23%)

TAK Takeda Pharmaceutical
$19.22 /

-0.045 (-0.23%)

Hot Stocks
Crocs' Poole sells 30,000 common shares » 18:53
05/28/20
05/28
18:53
05/28/20
18:53
CROX

Crocs

$28.75 /

-2.06 (-6.69%)

In a regulatory filing,…

In a regulatory filing, Crocs EVP, CP&M officer Michelle Poole disclosed the sale of 30,000 common shares of the company on May 26 at a price of $29.33 per share.

ShowHide Related Items >><<
CROX Crocs
$28.75 /

-2.06 (-6.69%)

CROX Crocs
$28.75 /

-2.06 (-6.69%)

05/22/20 B. Riley FBR
B. Riley FBR starts Crocs at Neutral, sees 10% downside potential
05/21/20 B. Riley FBR
Crocs initiated with a Neutral at B. Riley FBR
05/14/20 Susquehanna
Crocs price target raised to $27 from $25 at Susquehanna
05/11/20 Piper Sandler
Crocs price target raised to $28 from $24 at Piper Sandler
CROX Crocs
$28.75 /

-2.06 (-6.69%)

CROX Crocs
$28.75 /

-2.06 (-6.69%)

CROX Crocs
$28.75 /

-2.06 (-6.69%)

Hot Stocks
Salesforce CEO: Pipelines for Q2, Q3 'look amazing' » 18:44
05/28/20
05/28
18:44
05/28/20
18:44
CRM

Salesforce

$181.35 /

+4.78 (+2.71%)

, T

AT&T

$31.06 /

-0.79 (-2.48%)

In an interview on…

In an interview on CNBC's Mad Money, Marc Benioff said Q1 was challenging due to COVID-19 and the company's response to it. According to Benioff, pipelines "look amazing" for Q2 and Q3. He said he was "very optimistic" about Salesforce (CRM) and its ability to take share. He is "absolutely delighted" with the company's new agreement with AT&T (T).

ShowHide Related Items >><<
T AT&T
$31.06 /

-0.79 (-2.48%)

CRM Salesforce
$181.35 /

+4.78 (+2.71%)

CRM Salesforce
$181.35 /

+4.78 (+2.71%)

05/28/20 Needham
Workday price target raised to $200 from $175 at Needham
05/18/20 Jefferies
Salesforce price target raised to $205 from $180 at Jefferies
05/18/20 RBC Capital
Salesforce price target lowered to $210 from $230 at RBC Capital
05/18/20 Cowen
Salesforce price target lowered to $200 from $220 at Cowen
T AT&T
$31.06 /

-0.79 (-2.48%)

05/21/20 JPMorgan
Dish, AT&T's DirecTV combining could make sense, says JPMorgan
05/20/20 KeyBanc
T-Mobile price target raised to $126 from $104 at KeyBanc
05/05/20 Needham
Five9 price target raised to $115 from $82 at Needham
05/04/20 Needham
Ceragon longer-term news continues to improve, says Needham
T AT&T
$31.06 /

-0.79 (-2.48%)

CRM Salesforce
$181.35 /

+4.78 (+2.71%)

T AT&T
$31.06 /

-0.79 (-2.48%)

CRM Salesforce
$181.35 /

+4.78 (+2.71%)

T AT&T
$31.06 /

-0.79 (-2.48%)

CRM Salesforce
$181.35 /

+4.78 (+2.71%)

T AT&T
$31.06 /

-0.79 (-2.48%)

CRM Salesforce
$181.35 /

+4.78 (+2.71%)

Hot Stocks
PG&E commits to supporting CPUC's enactment of measures » 18:41
05/28/20
05/28
18:41
05/28/20
18:41
PCG

PG&E

$11.66 /

+0.71 (+6.48%)

Working with the…

Working with the Governor's Office and incorporating guidance from a February 2020 ruling from CPUC President Batjer, PG&E made a series of commitments regarding its governance, operations, and financial structure, all designed to further prioritize safety and expedite the company's successful emergence from Chapter 11. The commitments include: Supporting the CPUC's enactment of measures to strengthen PG&E's governance and operations, including enhanced regulatory oversight and enforcement that provides course-correction tools as well as stronger enforcement if it becomes necessary; Agreeing to host a State-appointed observer to provide the State with insight into the company's progress on safety goals before the company exits Chapter 11; Selecting a substantial number of new members of the Boards of Directors of PG&E Corporation and Pacific Gas and Electric Company upon emergence from Chapter 11; Appointing an independent safety monitor when the term of the court-appointed Federal Monitor expires; Establishing newly expanded roles of Chief Risk Officer and Chief Safety Officer, with both reporting directly to the PG&E Corporation CEO; Forming an Independent Safety Oversight Committee to provide independent review of operations, including compliance, safety leadership, and operational performance; Assuming all collective bargaining agreements with labor unions, pension obligations, and other employee obligations, and all power purchase agreements; Reforming executive compensation to further tie it to safety performance and customer experience; A commitment that PG&E Corporation will not reinstate a common stock dividend until it has recognized $6.2 billion in non-GAAP core earnings, which PG&E believes will contribute an additional $4 billion of equity to pay down debt and invest in the business; Pursuing a rate-neutral $7.5 billion securitization transaction after PG&E emerges from Chapter 11 in order to finance costs in an efficient manner that benefits customers and accelerates payment to wildfire victims; and committing not to seek recovery in customer rates of any portion of the amounts that will be paid to victims of the 2015, 2017, and 2018 wildfires under the Plan when PG&E emerges from Chapter 11, except through the rate-neutral securitization transaction.

ShowHide Related Items >><<
PCG PG&E
$11.66 /

+0.71 (+6.48%)

PCG PG&E
$11.66 /

+0.71 (+6.48%)

05/15/20 Barclays
Barclays upgrades Utilities sector along with PG&E and two others
05/15/20 Barclays
PG&E upgraded to Overweight from Equal Weight at Barclays
05/06/20 Mizuho
PG&E price target raised to $13.50 from $12.50 at Mizuho
05/04/20
Fly Intel: Top five analyst upgrades
PCG PG&E
$11.66 /

+0.71 (+6.48%)

PCG PG&E
$11.66 /

+0.71 (+6.48%)

PCG PG&E
$11.66 /

+0.71 (+6.48%)

PCG PG&E
$11.66 /

+0.71 (+6.48%)

Hot Stocks
CPUC approves PG&E's chapter 11 plan of reorganization » 18:39
05/28/20
05/28
18:39
05/28/20
18:39
PCG

PG&E

$11.66 /

+0.71 (+6.48%)

The California Public…

The California Public Utilities Commission approved the Chapter 11 Plan of Reorganization of PG&E Corporation and Pacific Gas and Electric Company. The CPUC approval in its Plan of Reorganization Order Instituting Investigation proceeding completes another major milestone needed for PG&E to be eligible to participate in the State's Wildfire Fund, and keeps the company on track for Bankruptcy Court confirmation of the Plan prior to June 30, 2020. The Bankruptcy Court confirmation hearing began on May 27, 2020. By adopting a final decision today, the CPUC approved a number of measures to improve PG&E's governance process, operational structure, and safety performance. Many of the measures outlined in the CPUC's final decision already are underway. The decision also approves PG&E's request to issue new debt and securities to finance its exit from Chapter 11. In addition to the CPUC's approval, on May 12, 2020, the Federal Energy Regulatory Commission issued its approval of the Plan, including authorizing the creation and funding of PG&E's proposed Fire Victim Trust. Under PG&E's Plan, the Fire Victim Trust will be established to administer and pay wildfire victim claims as provided in the Plan. The Plan does not raise customer rates and passes on approximately $1 billion in interest savings to customers. The Plan's financing provisions position PG&E to attract low-cost capital to fund its Wildfire Mitigation Plan to invest tens of billions of dollars in system hardening and wildfire risk mitigation in the coming years. As part of the Chapter 11 process, PG&E has previously reached settlements with all wildfire claimants' groups to be implemented pursuant to PG&E's Plan, valued at approximately $25.5 billion, including: An approximately $13.5 billion settlement resolving claims by individual victims and others relating to the 2015 Butte Fire, the 2017 Northern California Wildfires (including the 2017 Tubbs Fire), and the 2018 Camp Fire; this includes stock valued at $6.75 billion based on an agreed-upon formula (the ultimate value of the stock could be higher or lower); A $1 billion settlement with certain cities, counties, and other public entities; and an $11 billion settlement with insurance companies and other entities that paid claims by individuals and businesses related to the wildfires.

ShowHide Related Items >><<
PCG PG&E
$11.66 /

+0.71 (+6.48%)

PCG PG&E
$11.66 /

+0.71 (+6.48%)

05/15/20 Barclays
Barclays upgrades Utilities sector along with PG&E and two others
05/15/20 Barclays
PG&E upgraded to Overweight from Equal Weight at Barclays
05/06/20 Mizuho
PG&E price target raised to $13.50 from $12.50 at Mizuho
05/04/20
Fly Intel: Top five analyst upgrades
PCG PG&E
$11.66 /

+0.71 (+6.48%)

PCG PG&E
$11.66 /

+0.71 (+6.48%)

PCG PG&E
$11.66 /

+0.71 (+6.48%)

PCG PG&E
$11.66 /

+0.71 (+6.48%)

Hot Stocks
Merck, Eisai announce new data from KEYTRUDA plus LENVIMA trials » 18:38
05/28/20
05/28
18:38
05/28/20
18:38
MRK

Merck

$79.02 /

+1.46 (+1.88%)

Merck and Eisai announced…

Merck and Eisai announced new data from analyses of two trials evaluating KEYTRUDA, Merck's anti-PD-1 therapy, plus LENVIMA, an orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai. In the KEYNOTE-524/Study 116 and KEYNOTE-146/Study 111 trials, the KEYTRUDA plus LENVIMA combination demonstrated clinically meaningful objective response rates in patients with unresectable hepatocellular carcinoma with no prior systemic therapy and in patients with metastatic clear cell renal cell carcinoma who progressed following immune checkpoint inhibitor therapy, respectively. "The tumor response rates demonstrated with KEYTRUDA plus LENVIMA in these studies underscore the potential of this combination regimen in certain types of hepatocellular and renal cell carcinoma," said Dr. Jonathan Cheng, Vice President, Oncology Clinical Research, Merck Research Laboratories. "KEYTRUDA plus LENVIMA is an important pillar of our broad oncology research program, and we continue to advance the study of the combination across multiple types of cancers and stages of disease." "As data from our combination trials continue to read out, our enthusiasm for and belief in the potential of KEYTRUDA plus LENVIMA are strengthened by the growing body of evidence observed in multiple advanced cancers," said Dr. Takashi Owa, Chief Medicine Creation and Chief Discovery Officer, Oncology Business Group at Eisai. "Our ongoing clinical study efforts on this combination exemplify our commitment to following the science and exploring possible solutions for patients affected by difficult-to-treat cancers."

ShowHide Related Items >><<
MRK Merck
$79.02 /

+1.46 (+1.88%)

MRK Merck
$79.02 /

+1.46 (+1.88%)

05/27/20 Alliance Global Partners
PDS Biotechnology initiated with a Buy at Alliance Global Partners
05/20/20 JonesTrading
Merck collaboration positions Surface Oncology well, says JonesTrading
04/27/20 SVB Leerink
Clovis downgraded to Underperform at SVB Leerink as prostate opportunity fades
04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
MRK Merck
$79.02 /

+1.46 (+1.88%)

MRK Merck
$79.02 /

+1.46 (+1.88%)

MRK Merck
$79.02 /

+1.46 (+1.88%)

MRK Merck
$79.02 /

+1.46 (+1.88%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.